ZHONGSHENGYAOYE(SZ:002317) Nan Fang Du Shi Bao·2025-06-17 05:34Core Viewpoint - The launch of Anglave, the world's first innovative drug targeting the PB2 subunit of the RNA polymerase of the influenza A virus, represents a significant advancement in influenza treatment and showcases China's capability in drug innovation [1][2]. Innovation - Anglave is the first drug globally to target the PB2 subunit of the influenza virus RNA polymerase, approved for market on May 20 [2]. - The drug employs a unique "cap-snatching" mechanism, differing from the "endonuclease" mechanism used by other drugs, which had previously failed in clinical trials [2]. - Anglave is positioned as a "First-in-Class" drug, providing a new target for drug-resistant viruses and marking a shift in China's pharmaceutical innovation from "catching up" to "leading" [2]. Characteristics - The drug can significantly alleviate symptoms within one to three days, reducing viral load and making transmission less likely [3]. - Clinical studies show that Anglave shortens symptom relief time by nearly 40% compared to placebo and reduces fever duration by approximately 39% [3]. - The drug has a low resistance mutation rate, with suspected resistance rates of 0% and 1.6% in clinical phases II and III, respectively, and is effective against certain resistant "super flu viruses" [3]. - Anglave also has potential applications against highly pathogenic avian influenza viruses like H7N9 and H5N6, providing tools for managing avian-human transmission [3]. Production - All raw materials and excipients for Anglave are domestically sourced, ensuring a fully controllable production chain [4]. - The project involved collaboration among multiple institutions, integrating resources from virology, pharmacology, and clinical medicine, and was supported by various levels of policy [5]. - The successful development of Anglave exemplifies a new model of national collaboration in the biopharmaceutical sector in China [5].